LQDA gets FDA Fast Track for YUTREPIA® in Raynaud’s
FDA granted Fast Track designation to YUTREPIA® for treating Raynaud’s phenomenon associated with systemic sclerosis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.